Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX ± anlotinib for pancreatic acinar cell carcinoma
ChiCTR2600130583Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, fluorouracil, folinic acid and anlotinib in pancreatic acinar cell carcinoma (PACC) (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoints: Disease-Free Survival and Progression-Free Survival. Started Aug 2026; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidanlotinib
03
Conditions
pancreatic acinar cell carcinoma (PACC)
Beyond the preview
Go deeper on ChiCTR2600130583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130583.